Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
Valentina Gambardella, Pasquale Lombardi, Juan Antonio Carbonell‐Asins, Noelia Tarazona, Juan Miguel Cejalvo, Inés González‐Barrallo, Jorge Martín-Arana, R. Tébar-Martínez, Alba Viala, G. Bruixola, Cristina Hernándo, Inma Blasco, Federica Papaccio, Carolina Martínez‐Ciarpaglini, Clara Alfaro‐Cervelló, Enrique Seda, S. Blesa, Isabel Chirivella, Josefa Castillo, J. Montón-Bueno, Susana Roselló, Marisol Huerta, José Alejandro Pérez Fidalgo, Paloma Martín-Martorell, Amelia Insa-Mollá, Tania Fleitas, Pilar Rentero-Garrido, S. Zúñiga, Andrés Cervantes, Desamparados Roda
Abstract
INTRODUCTION: Molecular-matched therapies have revolutionized cancer treatment. We evaluated the improvement in clinical outcomes of applying an in-house customized Next Generation Sequencing panel in a single institution. METHODS: Patients with advanced solid tumors were molecularly selected to receive a molecular-matched treatment into early phase clinical trials versus best investigators choice, according to the evaluation of a multidisciplinary molecular tumor board. The primary endpoint was progression-free survival (PFS) assessed by the ratio of patients presenting 1.3-fold longer PFS on matched therapy (PFS2) than with prior therapy (PFS1). RESULTS: Of a total of 231 molecularly screened patients, 87 were eligible for analysis. Patients who received matched therapy had a higher median PFS2 (6.47 months; 95% CI, 2.24-14.43) compared to those who received standard therapy (2.76 months; 95% CI, 2.14-3.91, Log-rank p = 0.022). The proportion of patients with a PFS2/PFS1 ratio over 1.3 was significantly higher in the experimental arm (0.33 vs 0.08; p = 0.008). DISCUSSION: We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of a customized NGS panel. This process optimizes the selection of available therapies, improving disease control. Prospective randomized trials are needed to confirm this approach and open the door to expanded drug access.